DOI: 10.4244/EIJ-D-17-00364R

Bioresorbable vascular sca|ffold in chronic total occlusions

Jiang Ming Fam, MD; Roberto Diletti*, MD, PhD

We recently published acute angiographic, six-month CT scan and 12-month clinical results after everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in complex coronary chronic total occlusions1.

Dr Gerbay and Dr Isaaz highlighted the fact that, CTO being a complex lesion subset, a higher rate of reocclusion could be observed after BVS implantation compared with latest-generation drug-eluting stents. They also mentioned that reocclusion often remains clinically silent and it would be difficult to infer angiographic outcomes only from clinical symptoms. However, patency of bioresorbable devices can also be assessed by non-invasive imaging2,3. In our study, we reported computed tomography (CT) data in a subgroup of 34 patients at six-month follow-up, thus informing on the reocclusion rate in those lesions. Restenosis was observed in two cases: one patient was symptomatic and underwent target lesion revascularisation, while the other patient was asymptomatic, with no inducible ischaemia and was managed conservatively1. All patients were treated with dual antiplatelet therapy, consisting of aspirin plus P2Y12 inhibitors, as detailed in the study, for at least 12 months.

In addition to the CT scan, a long-term angiographic follow-up study with invasive imaging of the treated vessel is currently in preparation and will provide further information on the performance of bioresorbable devices in complex CTO lesions.

Finally, Dr Gerbay and Dr Isaaz commented that a randomised trial including a control group treated by latest-generation drug-eluting stents with a routine angiographic follow-up and long-term clinical outcome evaluation is necessary before extending the indication of BVS in CTOs. Such a statement is well accepted, but it should also be mentioned that randomised trials are often preceded by feasibility studies. As we concluded in our report, our results support the feasibility of BVS implantation in CTO lesions given an appropriate implantation technique and justify further research, including direct comparison with current-generation drug-eluting stents1.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Volume 13 Number 7
Sep 20, 2017
Volume 13 Number 7
View full issue


Key metrics

On the same subject

CLINICAL RESEARCH

10.4244/EIJ-D-16-00253 Jun 20, 2017
Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions
Fam J et al
free

10.4244/EIJ-D-17-00364L Sep 20, 2017
Bioresorbable vascular scaffold in chronic total occlusions
Gerbay A and Isaaz K
free
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved